Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 83Lung Neoplasms 29Neoplasms 7Neoplasm Metastasis 7Carcinoma 5Colorectal Neoplasms 4NSCLC 3Breast Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Non Small Cell Lung Cancer Metastatic 2Multiple Myeloma 2Meningeal Carcinomatosis 2Lymphoma 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stage II-IIIB Non-small Cell Lung Carcinoma 1Stage IB-IIIA Non-small Cell Lung Carcinoma 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Carcinoma 1

Interventions

pembrolizumab 6Injections 6senaparib 4toripalimab 3tislelizumab 3Nivolumab 3Bevacizumab 3sintilimab 2Technetium 2Specimen Handling 2Ipilimumab 2Fluorodeoxyglucose F18 2Carboplatin 2Blood Specimen Collection 2zimberelimab 1tumor-cells apoptosis factor, human 1tazemetostat 1spartalizumab 1sacituzumab govitecan 1rucaparib 1osimertinib 1olaparib 1etoposide phosphate 1enzalutamide 1envafolimab 1cemiplimab 1cedazuridine 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Ultrasonography, Doppler 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × osimertinib × 1 year × Clear all
NCT07612137 2026-05-28

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Not yet recruiting
282 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡